SCHEMBL5863181

SCHEMBL5863181

CCOC(=O)c1ccccc1-c1ccc(CSCCOc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
SCN1A P35498 2/20 0.46
SCN2A Q99250 2/20 0.46
SCN3A Q9NY46 2/20 0.46
TSHR P16473 3/20 0.44
MAPK10 P53779 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 2/20 0.43
NFKB1 P19838 2/20 0.43
RAB9A P51151 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTGER1 P34995 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863103 0.88 SMN1; SMN2 (0.45) SMN1; SMN2SCN1ASCN2ASCN3ATSHR
SCHEMBL5863068 0.86 TSHR (0.50) SCN1ASCN2ASCN3ATSHRMAPK10
SCHEMBL5863286 0.86 PTGER1 (0.47) ALDH1A1PTGER1PTGER4PTGER3PTGER2
SCHEMBL5863183 0.85 MAPT (0.53) SMN1; SMN2ALDH1A1RAB9AMEN1HPGD
SCHEMBL5863115 0.84 SMN1; SMN2 (0.49) SMN1; SMN2SCN1ASCN2ASCN3ATSHR
SCHEMBL5863113 0.81 MEN1 (0.51) SMN1; SMN2ALDH1A1NPC1RAB9AMEN1
SCHEMBL5863074 0.80 MAPT (0.50) SMN1; SMN2ALDH1A1RAB9AMEN1HPGD
SCHEMBL10460587 0.77 TSHR (0.51) SMN1; SMN2SCN1ASCN2ASCN3ATSHR
SCHEMBL8873262 0.76 TSHR (0.61) SCN1ASCN2ASCN3ATSHRMAPK10
SCHEMBL27686802 0.76 TSHR (0.65) SMN1; SMN2SCN1ASCN2ASCN3ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132456-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2006-11-07 US disclosed
US-20060052449-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2006-03-09 US disclosed
EP-1572637-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-09-14 EP disclosed
WO-2004052848-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052449-A1 Novel mch receptor antagonists MCHR1, MCHR2, MC1R SMN1; SMN2 1571/4885SCN1A 1284/4885SCN2A 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.